Judicialization of Zolgensma in the Ministry of Health: costs and clinical profile of patients.

Ana Katheryne Miranda Kretzschmar Ellen Teixeira Dayani Galato Everton Nunes da Silva

Published in: Revista de saude publica (2024)

The Ministry of Health incurs a high cost with the judicialization of Zolgensma for SMA, representing 2.45% of total spending on medicines in the Unified Health System, including spending by the three administrative spheres. Some of the lawsuits have been granted in disagreement with the criteria established by health technology assessment agencies and the drug manufacturer's recommendations.

Keyphrases

public health
healthcare
mental health
health information
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
health promotion
emergency department
human health
risk assessment
electronic health record
adverse drug